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Abstract
Prognosis prediction is a clinically relevant issue to facilitate optimal decision-making for 
both physicians and patients with cancer. Many previous studies revealed that prognosis 
prediction based on the physician’s intuition and/or clinical experience is inaccurate and 
often optimistic, which means that there is a tendency to overestimate patient survival 
in daily clinical practice. In recent decades, many efforts have been made to develop 
prognosis prediction models which aid physicians to make more accurate prognosis 
prediction. In this chapter, we review the representative prognosis prediction models in 
palliative care and related studies. In addition, we refer to several prognosis prediction 
models developed by unique methods (for instance, case-crossover design or machine 
learning). Finally, we focus on the possible clinical utility of prognosis prediction mod-
els. In fact, no previous studies have clearly demonstrated whether the application of 
such prognosis prediction models truly benefits patient care in daily clinical practice. 
Therefore, we will discuss how the application of prognosis prediction models could 
benefit patients under palliative care.
Keywords: cancer, clinical prediction of survival, clinical utility, palliative care, prognosis 
prediction model
1. Introduction
Prognosis is one of the most relevant concerns for both patients and healthcare professionals 
(HCPs). Patients with advanced cancer and their families are required to make decisions such 
as choosing treatment alternatives or place to spend their end of life or that of their  family 
members. In particular, timing in discontinuing palliative chemotherapy largely affects 
 end-of-life care. Continuing ineffective palliative chemotherapy at the end of life increases 
life-threatening adverse events (AEs), hospital administration associated with AEs, and 
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 medical cost [1, 2]. Furthermore, it causes patients’ quality of life (QOL) to deteriorate, delays 
hospice referral, and deprives patients of the chance to die in their preferred place [3, 4]. Thus, 
optimal prognosis prediction is essential for better end-of-life care.
Subjective prognosis prediction based on HCPs’ experience or intuition is a simple method, 
which requires no special device in daily practice. However, this method is often inaccurate or 
tends to overestimate patient survival [5]. Therefore, development of more accurate objective 
prognosis prediction methods is warranted.
In recent decades, several prognosis prediction models have been developed by integrating 
known prognostic factors [6–8]. These models have been validated in clinical settings across 
several countries and their accuracy have been compared [9, 10]. Moreover, studies exploit-
ing new prognostic factors, such as phase angle or circadian rhythm, have been reported in 
Refs. [11, 12].
Recent progress in informatics has enabled us to retrieve and analyze clinical big data 
 comprehensively, and new methods, such as machine learning or artificial intelligence, have 
been utilized to develop prognosis prediction models [13, 14]. We also review these issues in 
this chapter.
Finally, we focus on the clinical utility of prognosis prediction models, which has long been 
beyond the scope of the main issues in this research field.
2. Current status of prognosis prediction
2.1. Subjective prognosis prediction
Subjective prognosis prediction based on HCPs’ experience or intuition is referred to as clini-
cal prediction of survival (CPS). CPS is one of the most classic styles and has long been used 
in daily clinical practice. CPS utilizes three common questions. The first question is the “tem-
poral” question, asking “how long can the patient live?” The second question is the  “surprise” 
question, asking “will you be surprised if the patient dies within a specific term?” and the 
third question is the “probabilistic” question, asking “what is the patient’s probability of 
 survival within a specific term?”
The temporal question seems to be the most common prediction type in clinical practice. The 
answer to this question provides clear and simple information to HCPs. However, there are 
problems in its accuracy. Hui et al. reported its accuracy as just 32% among eight physicians 
and 18% among 20 nurses [15]. Moreover, 60% of nurses gave an optimistic prediction of 
survival [15]. Consistent with these results, another group reported that 63% of prognosis 
prediction estimated by HCPs was optimistic [16].
The surprise question has a feature of higher negative predictive value (NPV), which is more 
than 90% in two independent studies [17, 18]. Therefore, the surprise question has been used 
to identify patients who have a limited survival, and answering “no” is thought to signal the 
ideal time for specific action such as advance care planning (ACP) [19].
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The probabilistic question showed a higher accuracy than the temporal question. The accuracy 
of physicians’ prediction of death within 24 and 48 h was 71–73% and 66–67%, respectively 
[15, 20]. Interestingly, nurses showed more favorable predictive performance than physicians 
using the probabilistic question, and the accuracy of their prediction of death within 24 h and 
48 h was 90–91% and 83–86%, respectively [15, 20].
2.2. Objective prognosis prediction
As discussed in Section 2.1, each CPS may have promising performance in specific settings; 
however, their accuracy is not satisfactory and is often optimistic [5, 16, 21]. To cope with 
these problems, many efforts have been made to develop more accurate prognosis prediction 
models using known prognostic factors.
2.2.1. Prognostic factors
Prognostic factors are classified into two groups, one composed of clinical signs/symptom and 
the other of laboratory data. Performance status [22–24], dyspnea [25, 26], malnutrition [27, 
28], appetite/weight loss [29], and delirium [30, 31] are well-known clinical factors. Recently, 
novel prognostic factors have been proposed. Phase angle, which is measured via bioelectri-
cal impedance analysis (BIA), reflects the amount of water in tissues (resistance) and cellular 
membrane (capacitance) and could be a prognostic factor [11]. Circadian rhythm is also found 
to be an independent prognostic factor [12, 32].
Laboratory factors include inflammatory markers (for instance, C-reactive protein (CRP), 
erythrocyte sedimentation, or neutrophil lymphocyte ratio) [33, 34], nutrition markers (for 
instance, albumin) [35, 36], and tumor progression markers (for instance, calcium or lactate 
dehydrogenase) [37, 38].
2.2.2. Prognosis prediction model
In recent decades, many prognostic models have been developed integrating a variety of 
prognostic factors, CPS, and other patients’ information, and their accuracy is improving.
When we use these models in practice, we need to pay attention to the fitness of predic-
tion models for treating patients. In other words, we should verify the clinical settings under 
which the prediction model was developed. When the clinical settings for treating patients are 
similar to those of the original study, the prognostic model may fit that patient; otherwise, we 
should exercise caution when applying prognostic models.
We reviewed the previously proposed prognostic models in the palliative care setting as 
shown below and summarized the characteristics of each model in Table 1.
2.2.2.1. The palliative prognostic index (PPI)
The palliative prognostic index (PPI) is a noninvasive prognostic model developed by Morita 
et al. in 1999 and requires no laboratory items (Table 1) [6].
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Model Items Risk groups
Palliative prognostic index [6] Palliative prognostic index (0–4 points)
Oral intake (0–2.5 points)
Edema (0, 1 point)
Dyspnea at rest (0, 3.5 points)
Delirium (0, 4 points)
(A) Median survival 155 days: PPI ≤ 2.0
(B) Median survival 89 days: 2.0 < PPI 
≤ 4.0
(C) Median survival 18 days: 4.0 < PPI
Palliative prognostic score [7] Dyspnea (0, 1 point)
Anorexia (0, 1.5 points)
Karnofsky performance scale ≥ 50% (0, 
2.5 points)
Clinical prediction of survival (0–8.5 
points)
Total white blood cell (0–1.5 points)
Lymphocyte percentage (0–2.5 points)
(A) 30-Day survival probability 
> 70%, 0–5.5 points
(B) 30-Day survival probability 
30–70%, 5.6–11.0 points
(C) 30-Day survival probability 
< 30%, 11.1–17.5 points
Glasgow prognostic score [62] C-Reactive protein
Albumin
Score 0: C-Reactive protein ≥ 10 mg/l 
and albumin ≥ 35g/l
Score 1: C-reactive protein > 10 mg/l 
or albumin < 35 g/l
Score 2: C-reactive protein >10 mg/l 
and albumin < 35 g/l
Prognosis in palliative care study 
predictor models A [8]
Mental test score >3
Pulse rate
Presence of distant metastasis
Site of metastases (liver)
ECOG score
Global health score
Loss of appetite
Site of metastases (bone)
Difficulty in breathing
Difficulty in swallowing
Primary breast cancer
Primary male genital cancer 
(including prostate)
Weight loss
Days: <14 days
Weeks: 14–55 days
Months+: >55 days
*See detail in “THE PiPS 
PROGNOSTICATOR”
Prognosis in palliative care study 
predictor models B [8]
Pulse rate
White blood count
Platelets
Urea
C-Reactive protein
Global health score
Alanine transaminase
Mental test score >3
Distant metastasis
Site of metastases (bone)
Lack of appetite
ECOG score
Neutrophils
Lymphocytes
Alkaline phosphatase
Albumin
Primary male genital cancer 
(including prostate)
Tired
Days: <14 days
Weeks: 14–55 days
Months+: >55 days
*See detail in “THE PiPS 
PROGNOSTICATOR”
*THE PiPS PROGNOSTICATOR: http://www.pips.sgul.ac.uk/.
Table 1. Representative prognosis prediction models in palliative care.
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Validation studies of the PPI were performed in Japan, Taiwan, Kuwait, Ireland, the United 
Kingdom, and Australia [39–46]. Morita et al. revealed that the PPI significantly reduced overesti-
mation of survival compared to the CPS [39]. In the study of another group, the PPI was assessed 
by a nurse specialist, and the area under the curve (AUC) of the receiver operating characteristic 
(ROC) to predict death within 21 days was 0.68 [40]. In Kuwait, Alshemmari et al. revealed that 
the PPI can be a helpful tool in predicting hospital mortality of patients with advanced cancer 
in an acute care setting and that the hospital mortality rate for patients with a PPI score ≥ 6 was 
significantly higher than for those with a PPI score < 6 (93% versus 56% p < 0.001) [41].
In addition to the validation studies, studies which aimed to modify PPI were also reported. 
Two modified PPI models were tested in sub-analysis of the Japan-prognostic assessment 
tools validation (J-ProVal) study. The one substitutes the Communication Capacity Scale 
(CCS) for delirium to the required items of PPI [47]. The other adds a new item about the 
activities of daily living changes to the PPI; however, this did not significantly improve its 
prognostic value [48].
Moreover, some researchers examined the longitudinal score change of the PPI [49, 50].
2.2.2.2. Palliative prognostic (PaP) score
In 1999, Pirovano et al. proposed the palliative prognostic (PaP) score (Table 1) [7]. In this 
prospective cohort study, 519 patients with advanced cancer were recruited at 22 institutions 
in Italy, and a scoring model with a range of 0–17.5 points was developed. The score was able 
to subdivide the population into three risk groups [7]. The PaP score has been validated in 
both oncological and palliative settings.
In the palliative setting, the validation studies were performed in Australia, Italy, Brazil, and 
Canada [51–55]. Glare and Virik prospectively recruited 100 consecutive patients referred to 
palliative medicine consultative services. In this study, each of the three risk groups showed 
significantly different median survivals (60, 34, and 8 d, respectively) [51].
In the oncology setting, the validation studies were performed in Australia, Italy, and Japan 
[56–59]. Initially, a validation study of the oncology setting was reported by Glare et al. in 
2004, recruiting 100 patients receiving medical or radiation oncology care [56]. The median 
survival of three risk groups was 17, 7, and < 1 w, respectively. A retrospective study of 
Ikeguchi et al. was unique because it revealed that patients with non-resectable gastric cancer 
who were classified into the low-risk group by the PaP score received a more toxic first-line 
regimen, whereas patients with a high-risk score received a less toxic regimen [57]. Ikeguchi 
et al. concluded that the PaP score may be a promising tool for selecting a chemotherapy regi-
men for patients with non-resectable gastric cancer.
Studies modifying the PaP score are also reported. In 2011, Scarpi et al. proposed the D-PaP 
score, which added the item of delirium into the PaP score [60]. Interestingly, Hui et al. 
revealed that the PaP score without the CPS showed a better predictive performance than the 
original PaP score in 2016 [61]. This suggested that the addition of the CPS to the PaP score 
may actually reduce its accuracy. Further comparison of the PaP score with or without the CPS 
would be of value.
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2.2.2.3. Glasgow prognostic score (GPS)
The Glasgow prognostic score (GPS) is a simple prognostic model based on inflammatory 
markers, which requires only a CRP and albumin (Table 1). The GPS is a prognostic model 
with the most abundant evidence, and more than 60 papers recruiting more than 30,000 
 participants have been reported in Ref. [62].
However, studies of the GPS in a palliative care setting are scare. Partridge et al. retrospec-
tively examined the prognostic performance of 120 patients with advanced cancer at a single 
institution in the United Kingdom [63]. In this study, patients with a modified GPS of 2 had 
2.7 times higher risk of death compared to those with a modified GPS of 0 [63]. In the J-ProVal 
study, Miura et al. prospectively recruited 1160 patients in palliative care settings [64]. They 
reported that the positive predictive value (PPV) and NPV of 6 weeks of prognosis of patients 
with a GPS of 2 were 0.733 and 0.611, respectively.
2.2.2.4. Prognosis in palliative care study (PiPS) predictor model
In 2011, Gwilliam et al. proposed the prognosis in palliative care study (PiPS) model (Table 1). 
In this prospective cohort study, 1018 patients with cancer were recruited from 18 institutions 
in the United Kingdom [8]. The PiPS-A model does not require laboratory items and showed 
an AUC of 0.79. The PiPS-B model requires laboratory items and showed an AUC of 0.86.
Since the PiPS model is a relatively newer prognostic model, the number of validation studies 
is limited [65, 66]. In 2015, Kim et al. reported a validation study of 202 patients with advanced 
cancer at the palliative care unit (PCU) in Korea [65]. Both the PiPS-A model and the PiPS-B 
model effectively predicted median survival in the “days” and “weeks” groups; however, it did 
not in the “months” group [65]. Further validation of the PiPS model is warranted.
2.2.3. Comparison among prognosis prediction models
Direct comparison of different prognostic models in the same cohort is important, because it 
indicates the usefulness and appropriate clinical use of each model. There are some compara-
tive studies [9, 43, 67], and the largest is the J-ProVal study reported by Baba et al.
Baba et al. tested five different prognosis models: the PaP score, the D-PaP score, the PPI 
model, the PiPS-A model, and the PiPS-B model [10]. Concerning feasibility, prognostic 
models without laboratory tests (the PPI model and the PiPS-A model) showed more than 
90% feasibility in all palliative care settings, including home care services. Meanwhile, the 
feasibility of the PaP score, the D-PaP score, and the PiPS-B model, all of which require 
laboratory items, was 60–80%. In particular, the feasibility of home palliative care ser-
vices was only 30–40%. Concerning predictive value, the PPI showed a significantly lower 
C-index than the PaP score and the D-PaP score in almost all settings. The modified PiPS 
model showed equivalent or superior accuracy to the PaP score and the D-PaP score in 
all settings [10]. The authors concluded that the “PPI is simple and highly feasible, and 
seems to be suitable for routine clinical use for situations where rough estimates of prog-
nosis are sufficient and/or patients do not want invasive procedures. Although the PiPS-A 
model requires 13 items, it provides higher predictive value without invasive procedure. 
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If  laboratory items are available, the PaP score, D-PaP score and PiPS-B model would be 
more appropriate” [10].
2.2.4. Other prognosis prediction models
In addition to the abovementioned representative prognostic models, other prognostic 
 models are proposed, including the indicator of poor prognosis [68], the Vitamin B12/CRP 
index [69, 70], the terminal cancer prognostic score [71], the Chuang prognostic score [72, 73], 
the prognostic 7-day survival formula [74], the Chinese prognostic scale [75], the computer-
assisted model [76], the Japan palliative oncology study-prognostic index [77], the objective 
prognostic score [78, 79], the prognostic nomogram for terminally ill cancer patients [80], and 
the symptom-based predictive tool [81]. Further validation studies or comparative studies 
among those models are warranted.
2.2.5. Novel research fields of prognosis prediction models
2.2.5.1. Prediction of sudden unexpected death (SUD)
Prediction of sudden unexpected death (SUD) is a novel and pivotal research field. SUD has no 
clear definition, but it is often recognized as sudden death that occurs earlier than anticipated [82, 
83]. Prevalence of SUD ranges between 0.5 and 23% in the palliative care setting [82]. SUD shows 
no impending death sign, such as nonreactive pupils, decreased urine output, and peripheral 
cyanosis, which makes SUD more difficult to predict [82]. Meanwhile, SUD exposes patients, 
caregivers, and HCPs to serious burden [84]. Particularly, SUD is significantly associated with 
depression, panic disorder, alcohol use disorder, or social isolation for caregivers or bereaved 
families [85, 86]. Thus, identifying factors relating to the occurrence of SUD is richly warranted.
2.2.6. Prognosis prediction model using machine learning techniques or artificial intelligence
Because of the progress in the field of informatics, big data can be managed more easily and 
promptly than ever before. Correspondingly, the number of publications applying novel infor-
matics techniques is rising in clinical research. Prognosis prediction models using machine 
learning techniques or artificial intelligence have been proposed in the oncology setting [13, 
14]. In the coming decades, multidisciplinary studies featuring collaborations between infor-
matics specialists and HCPs are likely to be accelerated. In the palliative care setting, since 
invasive procedures are generally avoided, the amount of available clinical data—such as 
blood tests or imaging tests—is limited. This may cause delays in the progress of informatics 
in the palliative care setting. Therefore, improving data retrieving systems, including those 
subjective clinical symptoms recorded in text style (for instance, pain, nausea, and appetite 
loss), will play a key role in the progress of palliative care research.
3. Future plan
Many efforts, reviewed in this chapter, have been made toward developing prognostic mod-
els and improving their accuracy. We are also developing a novel prognosis prediction model, 
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which is “adaptable.” Conventional prognostic models are developed using the data obtained 
from a single time point (for instance, a baseline assessment date). This study design limits 
the use of these models under baseline conditions. Because patients’ condition during treat-
ment course can change from the baseline, development of an adaptable prognosis prediction 
model, which could be applied at any time point after the initiation of chemotherapy, is war-
ranted in practice. Thus, we are developing adaptable prognostic models for patients with 
cancer receiving chemotherapy [87]. In this case-crossover study, we recruited 2693 patients, 
and 3,471,521 laboratory data at 115,738 time points, representing 40 laboratory items that 
were monitored for 1 year before the death event, were applied in developing prognostic 
models. The prognosis prediction model utilizing albumin, lactate dehydrogenase, and neu-
trophils was selected based on its strong ability to predict death events within 1 month–6 
months, and the AUC for 1-month and 2-month models was more than 0.80. We plan to 
 compare this novel model with existing conventional models.
Meanwhile, apart from the effort to predict more accurate prognosis, we should also focus on 
the issue that no previous studies clearly demonstrated whether application of such progno-
sis prediction models truly benefits patient care in daily clinical practice. There are concerns 
that we may be satisfied merely with developing or using prognosis prediction models but 
pay less attention to assessing their clinical utility. Next, we consider how prognosis predic-
tion can benefit patients.
3.1. Efficacy of prognosis prediction for cancer patients
3.1.1. Clinical utility of prognostic disclosure
First, how many patients are willing to have their prognosis disclosed to them? Although 
it differs across studies, the proportion is reported to be 40–60% [88, 89]. It was shown that 
patients were willing to know their life expectancy in greater detail than anticipated by 
HCPs [90]. Thus, HCPs need to disclose the prognosis properly to patients who want this 
information.
Studies investigating the clinical outcome of prognostic disclosure are scarce. To the best of 
our knowledge, there are no clinical trials, but a few observational studies have been reported. 
In 2015, Enzinger et al. reported on a large prospective cohort study, “Coping with Cancer” 
[91]. In this study, 590 patients with advanced cancer were analyzed, and patients for whom 
their prognosis was disclosed had a more realistic understanding of life expectancy than 
those for whom it was not (median patient self-estimates of life expectancy 12 months versus 
48 months). Moreover, patients with a realistic understanding of life expectancy preferred 
comfort-oriented over life-prolonging care, with a higher likelihood of a do-not-resuscitate 
order without deteriorating the patients’ emotional well-being or the patient-physician 
 relationship [91]. Despite the limitation of being an observational study, however, this study 
produced meaningful findings for the association between prognosis disclosure and advance 
care planning (ACP).
Many studies have investigated whether ACP benefited end-of-life management. In the 
“Coping with Cancer” study, Wright et al. showed that end-of-life discussion was significantly 
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associated with a less aggressive medical care (such as ventilation, ICU admission, and resus-
citation), a reduction in the bereaved caregiver’s grief or depression, and a longer hospice 
stay [92]. Other similar studies also showed consistent results [1, 93, 94].
3.1.2. Clinical utility of prognosis prediction model
The outcomes of prognosis disclosure based on prognostic models would be expected to be 
the same as the outcomes referred to in Section 3.1.1. Considering study design is a challeng-
ing issue. For example, prognosis disclosure based on prognostic models versus the CPS may 
be interesting, but it may also introduce some ethical issues that need to be resolved. We hope 
that the number of studies investigating the clinical utility of prognostic models will increase 
in the near future.
4. Conclusion
A number of prognosis prediction models are proposed, and their accuracy is approaching 
80–90%. Novel techniques, such as machine learning or artificial intelligence, would acceler-
ate progress. At the same time, we need to put greater efforts to clarify the clinical utility of 
prognosis prediction models for patients with cancer, a topic that has been beyond the scope 
of the main issues in this research field for a long time.
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